Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avital M Miller

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Cancer Medicine|August 29, 2025
Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta-Epidemiological AnalysisGabrielle Brown, Pavlos Msaouel, Avital M Miller, et al.
JCO Oncology Practice|January 8, 2025
Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology TrialsAvital M Miller, Adina H Passy, Alexander D Sherry, et al.
Cancer|February 7, 2026
Control arm overperformance in phase 3 oncology clinical trialsAnsel P Nalin, Pavlos Msaouel, Adam J Grippin, et al.
Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS|September 5, 2025
Mastectomy and breast augmentation outcomes among nonbinary, transgender, and cisgender adultsAmitai S Miller, Maria J Escobar-Domingo, Avital M Miller, et al.
JCO Clinical Cancer Informatics|August 30, 2024
Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point AnalysesAlexander D Sherry, Adina H Passy, Zachary R McCaw, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2025
Reproducibility of statistically significant phase III oncology trials: An In Silico meta-epidemiological analysisAlexander D Sherry, Pavlos Msaouel, Avital M Miller, et al.
Journal of the National Cancer Institute|December 10, 2024
Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological studyTroy J Kleber, Alexander D Sherry, Andrew J Arifin, et al.
British Journal of Cancer|August 11, 2025
Bayesian interim analysis and efficiency of phase III randomized trialsAlexander D Sherry, Pavlos Msaouel, Avital M Miller, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Bayesian Interim Analysis and Efficiency of Phase III Randomized TrialsAlexander D Sherry, Pavlos Msaouel, Avital M Miller, et al.
JAMA Oncology|June 1, 2025
Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological AnalysisAlexander D Sherry, Avital M Miller, Jnana Preeti Parlapalli, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Cancer Medicine|August 29, 2025
Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta-Epidemiological AnalysisGabrielle Brown, Pavlos Msaouel, Avital M Miller, et al.
JCO Oncology Practice|January 8, 2025
Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology TrialsAvital M Miller, Adina H Passy, Alexander D Sherry, et al.
Cancer|February 7, 2026
Control arm overperformance in phase 3 oncology clinical trialsAnsel P Nalin, Pavlos Msaouel, Adam J Grippin, et al.
Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS|September 5, 2025
Mastectomy and breast augmentation outcomes among nonbinary, transgender, and cisgender adultsAmitai S Miller, Maria J Escobar-Domingo, Avital M Miller, et al.
JCO Clinical Cancer Informatics|August 30, 2024
Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point AnalysesAlexander D Sherry, Adina H Passy, Zachary R McCaw, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2025
Reproducibility of statistically significant phase III oncology trials: An In Silico meta-epidemiological analysisAlexander D Sherry, Pavlos Msaouel, Avital M Miller, et al.
Journal of the National Cancer Institute|December 10, 2024
Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological studyTroy J Kleber, Alexander D Sherry, Andrew J Arifin, et al.
British Journal of Cancer|August 11, 2025
Bayesian interim analysis and efficiency of phase III randomized trialsAlexander D Sherry, Pavlos Msaouel, Avital M Miller, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Bayesian Interim Analysis and Efficiency of Phase III Randomized TrialsAlexander D Sherry, Pavlos Msaouel, Avital M Miller, et al.
JAMA Oncology|June 1, 2025
Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological AnalysisAlexander D Sherry, Avital M Miller, Jnana Preeti Parlapalli, et al.
Pageof 2